Lapatinib is a reversible, first-generation inhibitor of EGFR type 1 (HER1) and type 2 (HER2), administered orally and approved for the treatment of breast cancer overexpressing HER2 in combination with capecitabine [28]. This evidence concerns the gene ERBB2 and breast cancer.